Which of These Resources Contain Information on HHS-Regulated Drug Testing Programs: A Deep Dive

The most reliable resources containing information on HHS-regulated drug testing programs are the Substance Abuse and Mental Health Services Administration (SAMHSA) website and the eCFR (Title 49, Part 40). SAMHSA administers the Mandatory Guidelines for federal workplace testing, while the eCFR publishes the procedural rules. Manufacturer package inserts and CAP inspection checklists also contain program-relevant information, but only within narrower scopes. Peer-reviewed journals and commercial lab brochures are secondary at best.

SAMHSA sits inside the Department of Health and Human Services, and that placement is why "HHS-regulated" and "SAMHSA-certified" are often used interchangeably in workplace testing. The distinction matters because the regulatory authority, the procedural rulebook, and the certified-lab list live in three different places.

The regulatory architecture behind HHS drug testing

Federal workplace drug testing rests on two parallel documents. The Mandatory Guidelines for Federal Workplace Drug Testing Programs, published by SAMHSA in the Federal Register, define the scientific and technical standards: which specimens are authorized, which analytes are tested, what cutoff concentrations apply, and what review procedures protect donors. The Department of Transportation's 49 CFR Part 40 defines the procedural side for DOT-regulated industries: collector training, custody-and-control form requirements, medical review officer duties, and split-specimen handling.

The two documents reference each other but are not identical in scope. SAMHSA's guidelines govern the scientific validity of the laboratory result. Part 40 governs the human chain of custody that makes the result defensible. A resource that covers only one is incomplete for anyone asking how the program actually works end to end.

The certification mechanism is the connective tissue. Laboratories must be certified by HHS before they can test federal employees or DOT-regulated workers. SAMHSA maintains the official list of certified laboratories and publishes the criteria each lab must meet. That list is the single most authoritative resource for verifying whether a lab is genuinely HHS-certified rather than self-declared.

The vertical structure matters because a "HHS-compliant" label on a test kit, a rapid device, or a lab's marketing page does not mean the product or service is approved under the Mandatory Guidelines. Only items on the SAMHSA-published lists carry that status.

What each resource actually covers

Different resources cover different slices of the program. The table below compares the main categories.

The SAMHSA website and the eCFR are the two primary sources. Everything else is either derivative or narrowly scoped. A package insert, for example, tells you what a device claims to detect at what threshold, but it does not tell you whether that threshold matches the federal program's cutoff. Only the Mandatory Guidelines answer that.

The Federal Register is the resource most people overlook. When SAMHSA adds an analyte to the testing panel, the change appears first as a proposed rule, then as a final rule with an effective date. Anyone trying to determine whether a specific substance is covered on a given date needs the Federal Register, not a secondary summary that may be years out of date.

Where the same fact lives in multiple places

Cutoff concentrations illustrate the reconciliation problem well. The Mandatory Guidelines publish initial test cutoffs and confirmatory test cutoffs for each authorized analyte. A laboratory's internal standard operating procedure restates those cutoffs. A manufacturer's package insert may list a screening cutoff that differs from the federal initial test cutoff. A clinical guideline from a medical society may reference yet another number for a different purpose.

These are not contradictions. They are different thresholds serving different functions. The federal initial test cutoff is a screening threshold set to minimize false negatives in workplace populations. The confirmatory cutoff is set higher to minimize false positives before an adverse action. A point-of-care device's cutoff is set by the manufacturer for its own intended use and may not align with either.

The professional caveat here is that a result reported against a non-federal cutoff cannot be treated as equivalent to a federal program result. A donor who screens positive at a clinical threshold may screen negative at a federal initial cutoff, and vice versa. Reconciling the two requires reading the specific document that defines the threshold in question.

Plain language: the same drug can produce different answers depending on which cutoff the test used, so always identify the cutoff before comparing results.

Edge cases that trip up program administrators

Specimen validity testing is the edge case most often mishandled. Federal rules require laboratories to evaluate specimens for dilution, adulteration, and substitution before reporting a result. A specimen that is too dilute may be reported as negative, but the program may require recollection under direct observation. Resources that describe only the drug result and omit validity testing give an incomplete picture.

Split-specimen testing is another. When a donor requests testing of the split specimen, the second aliquot is tested by a different laboratory. A resource that does not explain the split-specimen process cannot answer how a non-negative result gets confirmed or challenged.

The medical review officer interview is the third. An MRO must interview the donor and review the donor's medical history before reporting a verified positive result. Programs that skip this step, or resources that omit it, produce results that may not survive challenge.

Red flags to watch for in any resource: Claims of "HHS-approved" test kits, since approval applies to laboratories, not devices. Cutoff tables with no citation to the governing document or publication date. Descriptions of testing panels that omit specimen validity testing. Statements that a result is "final" without mention of the MRO review. Certification claims that cannot be checked against the SAMHSA published list. Guidance that conflates DOT procedural rules with SAMHSA scientific standards.

A short timeline of how the standards developed

The program has changed materially over time, and dated resources may describe superseded standards.

The practical consequence is that any resource older than the most recent revision of the Mandatory Guidelines may describe cutoffs, panels, or procedures that no longer apply. Checking the effective date of the governing document is the fastest way to judge whether a resource is current.

Misconceptions about HHS-regulated programs

The most common misconception is that HHS certifies individual drug test devices. It does not. HHS certifies laboratories under the Mandatory Guidelines, and SAMHSA publishes the list of certified labs. A device may be cleared by the FDA for a stated intended use, but that is a separate regulatory pathway with different requirements.

A second misconception is that a negative result on a rapid point-of-care device meets federal program requirements. Federal workplace testing requires laboratory analysis using authorized methods, and rapid devices are not a substitute for laboratory confirmation.

A third is that the program applies uniformly to all employers. The Mandatory Guidelines govern federal agency testing and, through DOT rules, safety-sensitive transportation workers. Private employers may follow the guidelines voluntarily, but they are not required to, and their programs may differ in panel, cutoff, and procedure.

A fourth is that "HHS-certified" and "CLIA-certified" are interchangeable. They are different programs with different standards. CLIA certification covers clinical laboratory testing broadly. HHS certification under the Mandatory Guidelines covers workplace drug testing specifically, with additional requirements on chain of custody and MRO review.

Practical steps to verify a resource

Start with the SAMHSA website. Confirm the resource cites the current Mandatory Guidelines and includes a publication or effective date. Cross-check any laboratory named in the resource against the published certified lab list. Then check the eCFR for the procedural rules if the program involves DOT-regulated workers.

For a specific analyte or cutoff, go to the Federal Register notice that adopted it. Secondary summaries should match that notice; if they do not, trust the notice.

For device claims, read the package insert and compare its cutoff to the federal cutoff in the Mandatory Guidelines. If they differ, the insert is describing the device's intended use, not the federal standard.

Set a review cadence. Recheck the SAMHSA site and the eCFR at least annually, and immediately after any Federal Register notice affecting the program. Archive the version you relied on, because the standards change and older versions become unreachable.

Limitations of what these resources can tell you

No public resource will tell you whether a specific donor's result is valid in a specific case. That determination requires the laboratory's records, the MRO's review, and the program's procedural history. Public resources define the rules; they do not apply them to individual cases.

The scientific literature can explain why a cutoff was chosen, but it cannot tell you what cutoff applies in your program on a given date. That answer comes only from the governing document in effect at the time.

Finally, resources describe the federal program, not every state or employer program. State law and collective bargaining agreements can impose additional requirements, and no federal resource captures them.

This article is general educational information about where to find regulatory resources. It is not a diagnosis, treatment plan, legal opinion, or compliance determination for any specific program or individual. Consult a qualified compliance professional, laboratory director, or attorney for guidance on a specific testing program or result.